15 February 2018 (Thursday) - Oncologist Newsletter



Here’s an interesting review of Daratumumab which came in the Oncologist newsletter this morning. Daratumumab seems to be a rather valuable treatment; a shame that it is seen as a nuisance in the lab as it interferes with blood group antibody screening…

No comments:

Post a comment